

**Jazz Pharmaceuticals, Inc.** (Nasdaq: JAZZ) is a specialty pharmaceutical company that identifies, develops and commercializes innovative products for unmet medical needs in neurology and psychiatry.

Jazz Pharmaceuticals has an unwavering commitment to improving care for patients with serious neurological and psychiatric conditions through innovative products and distinctive, valuable programs for patients and physicians. Collaboration with key constituencies, including physicians, patients and industry partners, facilitates innovation and ensures therapeutics and new product candidates fulfill important medical needs.

Jazz Pharmaceuticals has built its pipeline by expertly leveraging novel formulations and drug delivery technologies to advance known and/or well-characterized compounds. This lower-risk model enables the company to maintain its focus on patient care with the goal of improving product efficacy, reducing adverse side effects and increasing patient compliance relative to existing therapies.

### Products & Pipeline

Jazz Pharmaceuticals' development portfolio also includes JZP-4, JZP-7, and JZP-8. JZP-4 is a controlled-release formulation of elpetrigine, a new chemical entity that combines two mechanisms known to work well in anti-epileptic drugs: it is both a sodium channel and calcium channel blocker. JZP-4 has completed human proof-of-concept studies in epilepsy and also has promise in bipolar disorder. JZP-7 is a once-daily transdermal gel of ropinirole for the treatment of restless legs syndrome. JZP-8 is an intranasal formulation of clonazepam for the treatment of acute repetitive seizures. Consistent with its commitment to addressing areas of unmet neurological and psychiatric need, the company is identifying and evaluating product candidates with the goal of providing innovative solutions to these patients in need.



**XYREM**  
(sodium oxybate) oral solution



**LUVOX CR**  
fluvoxamine maleate extended-release capsules

	Clinical Development	Marketed
	Cataplexy and Excessive Daytime Sleepiness in Narcolepsy	
	Obsessive Compulsive Disorder and Social Anxiety Disorder	
JZP-6	Fibromyalgia	Filed
JZP-7	Restless Legs Syndrome Phase II	
JZP-8	Acute Repetitive Seizures Phase II	
JZP-4	Epilepsy/Bipolar Disorder Phase I	

### Fast Facts

**Founded:** 2003

**NASDAQ Symbol:** JAZZ

**Headquarters:** Palo Alto, California

**Employees:** 220

**2009 Revenues:** \$128 million

### Products

XYREM® (sodium oxybate) approved for the treatment of excessive daytime sleepiness and cataplexy, in patients with Narcolepsy.

LUVOX CR® (fluvoxamine maleate) Extended Release Capsules approved for the treatment of Social Anxiety Disorder and Obsessive Compulsive Disorder.

### Commercial Operations

Jazz Pharmaceuticals markets XYREM and LUVOX CR in the United States through its specialty sales force. UCB markets XYREM in Europe and Valeant Canada Ltd. markets XYREM in Canada.

### Key Pipeline Products

JZP-6: Fibromyalgia

JZP-7: Restless Legs Syndrome

JZP-8: Acute Repetitive Seizures

JZP-4: Epilepsy & Bipolar Disorder

### Analyst Coverage

Barclays Capital  
Jefferies & Company  
Lazard Capital Markets  
WBB Securities

### Investor Relations Contact

Ph: +1-650-496-2800

investorinfo@jazzpharmaceuticals.com

## Products



XYREM® (sodium oxybate) is the only FDA-approved therapy for the treatment of the two most common daytime symptoms of narcolepsy, excessive daytime sleepiness (EDS) and cataplexy. Narcolepsy is a chronic and debilitating neurological sleep disorder caused by the brain's inability to regulate sleep-wake cycles. Narcolepsy is estimated to affect 1 in 2,000 people in the U.S., but fewer than 85,000 are diagnosed.



LUVOX CR®, a selective serotonin reuptake inhibitor (SSRI), is approved for the treatment of social anxiety disorder (SAD) and obsessive compulsive disorder (OCD), two difficult-to-treat, underdiagnosed and undertreated anxiety disorders. SAD affects approximately 15 million American adults, and OCD affects approximately 2.2 million American adults.

## Product Development Candidates

Jazz Pharmaceuticals' development-stage product candidates were selected based on a clear medical need, and each is advanced to the next phase of development only after passing rigorous proof-of-concept evaluation in early studies.

The company's most advanced agent in development is JZP-6 (sodium oxybate) for the treatment of fibromyalgia, a chronic pain condition affecting approximately 6-12 million Americans. A New Drug Application (NDA) for JZP-6 was accepted for filing by the U.S. Food and Drug Administration (FDA) in February 2010. Based on a standard 10-month review, the target date for the FDA to complete its review of the NDA under the Prescription Drug User Fee Act (PDUFA) is October 11, 2010.

## Commitment

Jazz Pharmaceuticals has supported patient advocacy groups to further public education and to develop unique resources for patients and physicians, including diagnostic screening tools, disease education websites and a patient assistance program. The programs are intended to increase awareness and improve knowledge of often misunderstood conditions, such as narcolepsy, OCD and SAD, and to help ensure that patients receive accurate diagnosis and access to effective treatment. Jazz Pharmaceuticals also seeks direct feedback from physicians through occasional scientific and medical advisory board meetings and consults with key opinion leaders in neurology and psychiatry to gain valuable insight into important unmet medical needs.

Please visit Jazz Pharmaceuticals at [www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com).

## Management

Jazz Pharmaceuticals' management team has a proven track record of successfully developing and commercializing medical treatments that deliver results.

**Bruce C. Cozadd**  
*Chairman and CEO*

**Robert M. Myers**  
*President*

**Kathryn E. Falberg**  
*SVP, Chief Financial Officer*

**Carol A. Gamble**  
*SVP, General Counsel & Corporate Secretary*

**Janne L. T. Wissel**  
*SVP, Chief Regulatory Officer & Chief Compliance Officer*

**Michael DesJardin**  
*SVP, Product Development*

**Mark G. Eller, Ph.D.**  
*SVP, Research & Clinical Development*

**Diane R. Guinta, Ph.D.**  
*VP, Clinical Research & Development*

**P.J. Honerkamp**  
*VP, Deputy General Counsel*

**Edwin W. Luker**  
*VP, Sales*

**Annette Madrid, MD**  
*VP, Clinical and Experimental Medicine & Chief Medical Officer*

**Heather McGaughey**  
*VP, Human Resources*

**Joel M. Rothman**  
*VP, Development Operations*

## Board of Directors

**Paul L. Berns**  
*Allos Therapeutics, Inc.*

**Samuel D. Colella**  
*Versant Ventures*

**Bruce C. Cozadd**  
*Jazz Pharmaceuticals*

**Bryan C. Cressey**  
*Cressey & Company LP*

**Patrick Enright**  
*Longitude Capital*

**Michael W. Michelson**  
*Kohlberg Kravis Roberts & Co. L.P.*

**James C. Montazee**  
*Kohlberg Kravis Roberts & Co. L.P.*

**Robert M. Myers**  
*Jazz Pharmaceuticals*

**Kenneth W. O'Keefe**  
*Beecken Petty O'Keefe & Company*

**Alan M. Sebulsky**  
*Apothecary Capital LLC*

**James B. Tananbaum, MD**  
*Prospect Venture Partners*

**Rick E. Winningham**  
*Theravance, Inc.*

**Nathaniel M. Zilkha**  
*Kohlberg Kravis Roberts & Co. L.P.*